[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fEwn4qYsdSgvY9tLvDPzDUnyzPcM7r5G3SV8N8l6PbBQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"Université de Sherbrooke",[4],293,false,68,15,59404,17,241,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Healthy",14,{"name":18,"count":19},"Chronic Pain",13,{"name":21,"count":22},"Obesity",12,{"name":24,"count":25},"Type 2 Diabetes",9,{"name":27,"count":28},"Stroke",7,{"name":30,"count":31},"Gestational Diabetes Mellitus",6,{"name":33,"count":34},"Asthma",5,{"name":36,"count":37},"Heart Failure",4,[39,44,49,54,59,64,69,74,79,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05148715","Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)","2025-12","Tacrolimus",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT03672721","IA Carboplatin + Radiotherapy in Relapsing GBM","2025-12-10","IA Carbo+ Radiation",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06651112","The ATP Project (Antipsychotic-TEP-Psychosis)","2026-11-01","Antipsychotic drugs",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT07396857","The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting","2026-12-15","Fluconazole 150 mg",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04227678","Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency","2026-12-30","Heparin",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT00223171","Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers","2026-12-31","Androgen blockade + radiation therapy",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06356883","Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma","2027-04","IA Carboplatin + IA Caelyx",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT06261502","Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome","2027-12-01","CBD Oral Solution",{"nctId":80,"briefTitle":81,"date":82,"intervention":78},"NCT06261450","Effect of CBD on the Brain","2027-12-15",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT05934409","Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery","2028-01-31","Nicotinic Acid",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,131,149,167,185,211,234,262,286,312,335,357,375,408,430,450,478,502,529,554,585,603,630,648,676,694,719,746,764,794,836,854,880,898,923,947,974,1000,1018,1041,1066,1090,1116,1140,1166,1184,1209,1234,1259,1294,1318,1347,1365,1391,1416,1441,1465,1489,1513,1537,1555,1579,1603],{"intervention":97,"totalTrials":98,"cells":99},"1- Vasopressor - Mean arterial pressure 56-60",1,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":127,"NA":129},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":98,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":123},"NCT06605144","Canadian Critical Care Comparative Effectiveness Platform","RECRUITING",[92],"2029-12-31","2030-06-30","2025-03-23",5500,[119,120,121,122],"Intensive Care Unit ICU","Vasopressor","Platelet","Nutrition",[97,124,125,126],"2- Vasopressor - Mean arterial pressure 61-65","3- Vasopressor - Mean arterial pressure 66-70","4- Vasopressor - Mean arterial pressure 71-75",{"trials":128,"activeCount":102},[],{"trials":130,"activeCount":102},[],{"intervention":124,"totalTrials":98,"cells":132},{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":145,"NA":147},{"trials":134,"activeCount":102},[],{"trials":136,"activeCount":102},[],{"trials":138,"activeCount":102},[],{"trials":140,"activeCount":98,"soonestReadout":114},[141],{"nctId":110,"briefTitle":111,"status":112,"phases":142,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":143,"interventions":144},[92],[119,120,121,122],[97,124,125,126],{"trials":146,"activeCount":102},[],{"trials":148,"activeCount":102},[],{"intervention":125,"totalTrials":98,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":163,"NA":165},{"trials":152,"activeCount":102},[],{"trials":154,"activeCount":102},[],{"trials":156,"activeCount":102},[],{"trials":158,"activeCount":98,"soonestReadout":114},[159],{"nctId":110,"briefTitle":111,"status":112,"phases":160,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":161,"interventions":162},[92],[119,120,121,122],[97,124,125,126],{"trials":164,"activeCount":102},[],{"trials":166,"activeCount":102},[],{"intervention":126,"totalTrials":98,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":181,"NA":183},{"trials":170,"activeCount":102},[],{"trials":172,"activeCount":102},[],{"trials":174,"activeCount":102},[],{"trials":176,"activeCount":98,"soonestReadout":114},[177],{"nctId":110,"briefTitle":111,"status":112,"phases":178,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":179,"interventions":180},[92],[119,120,121,122],[97,124,125,126],{"trials":182,"activeCount":102},[],{"trials":184,"activeCount":102},[],{"intervention":186,"totalTrials":98,"cells":187},"Dupilumab Prefilled Syringe",{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":207,"NA":209},{"trials":189,"activeCount":102},[],{"trials":191,"activeCount":102},[],{"trials":193,"activeCount":102},[],{"trials":195,"activeCount":98,"soonestReadout":200},[196],{"nctId":197,"briefTitle":198,"status":112,"phases":199,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT07309614","A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma",[92],"2029-01","2030-01","2026-01-29",150,[205],"Asthma Control",[186],{"trials":208,"activeCount":102},[],{"trials":210,"activeCount":102},[],{"intervention":68,"totalTrials":98,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":230,"NA":232},{"trials":214,"activeCount":102},[],{"trials":216,"activeCount":102},[],{"trials":218,"activeCount":102},[],{"trials":220,"activeCount":98,"soonestReadout":67},[221],{"nctId":65,"briefTitle":66,"status":222,"phases":223,"primaryCompletion":67,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"ACTIVE_NOT_RECRUITING",[92],"2027-12-31","2000-10",630,[228],"Prostate Cancer",[68],{"trials":231,"activeCount":102},[],{"trials":233,"activeCount":102},[],{"intervention":78,"totalTrials":235,"cells":236},2,{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":256,"PHASE4":258,"NA":260},{"trials":238,"activeCount":102},[],{"trials":240,"activeCount":102},[],{"trials":242,"activeCount":235,"soonestReadout":77},[243,251],{"nctId":80,"briefTitle":81,"status":244,"phases":245,"primaryCompletion":82,"completion":82,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NOT_YET_RECRUITING",[91],"2025-05-01",50,[249],"Fragile X Syndrome",[78],{"nctId":75,"briefTitle":76,"status":244,"phases":252,"primaryCompletion":77,"completion":77,"start":246,"enrollment":253,"conditions":254,"interventions":255},[91],40,[249],[78],{"trials":257,"activeCount":102},[],{"trials":259,"activeCount":102},[],{"trials":261,"activeCount":102},[],{"intervention":43,"totalTrials":98,"cells":263},{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":280,"PHASE4":282,"NA":284},{"trials":265,"activeCount":102},[],{"trials":267,"activeCount":102},[],{"trials":269,"activeCount":98,"soonestReadout":42},[270],{"nctId":40,"briefTitle":41,"status":222,"phases":271,"primaryCompletion":42,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":279},[91],"2026-01","2022-07-11",414,[276,277,278],"Organ Transplant Failure or Rejection","Brain Death","Ischemic Reperfusion Injury",[43],{"trials":281,"activeCount":102},[],{"trials":283,"activeCount":102},[],{"trials":285,"activeCount":102},[],{"intervention":287,"totalTrials":98,"cells":288},"Celecoxib",{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":306,"PHASE4":308,"NA":310},{"trials":290,"activeCount":102},[],{"trials":292,"activeCount":102},[],{"trials":294,"activeCount":98,"soonestReadout":299},[295],{"nctId":296,"briefTitle":297,"status":112,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT07104266","Triple Negative Breast Cancer and Celecoxib. Pilot Study",[91],"2028-08-04","2032-08-04","2025-08-04",30,[304],"Triple-Negative Breast Cancer",[287],{"trials":307,"activeCount":102},[],{"trials":309,"activeCount":102},[],{"trials":311,"activeCount":102},[],{"intervention":48,"totalTrials":98,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":329,"PHASE4":331,"NA":333},{"trials":315,"activeCount":102},[],{"trials":317,"activeCount":102},[],{"trials":319,"activeCount":98,"soonestReadout":47},[320],{"nctId":45,"briefTitle":46,"status":112,"phases":321,"primaryCompletion":47,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":328},[90,91],"2026-06-10","2018-07-10",35,[326,327],"Glioblastoma Multiforme","Relapse",[48],{"trials":330,"activeCount":102},[],{"trials":332,"activeCount":102},[],{"trials":334,"activeCount":102},[],{"intervention":73,"totalTrials":98,"cells":336},{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":351,"PHASE4":353,"NA":355},{"trials":338,"activeCount":102},[],{"trials":340,"activeCount":102},[],{"trials":342,"activeCount":98,"soonestReadout":72},[343],{"nctId":70,"briefTitle":71,"status":112,"phases":344,"primaryCompletion":72,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":349},[91],"2028-04","2025-08",120,[326,327],[73,350],"IA Carboplatin + IA Etoposide Phosphate",{"trials":352,"activeCount":102},[],{"trials":354,"activeCount":102},[],{"trials":356,"activeCount":102},[],{"intervention":350,"totalTrials":98,"cells":358},{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":369,"PHASE4":371,"NA":373},{"trials":360,"activeCount":102},[],{"trials":362,"activeCount":102},[],{"trials":364,"activeCount":98,"soonestReadout":72},[365],{"nctId":70,"briefTitle":71,"status":112,"phases":366,"primaryCompletion":72,"completion":345,"start":346,"enrollment":347,"conditions":367,"interventions":368},[91],[326,327],[73,350],{"trials":370,"activeCount":102},[],{"trials":372,"activeCount":102},[],{"trials":374,"activeCount":102},[],{"intervention":87,"totalTrials":235,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":387},{"trials":378,"activeCount":102},[],{"trials":380,"activeCount":102},[],{"trials":382,"activeCount":102},[],{"trials":384,"activeCount":102},[],{"trials":386,"activeCount":102},[],{"trials":388,"activeCount":98,"soonestReadout":86},[389,396],{"nctId":84,"briefTitle":85,"status":112,"phases":390,"primaryCompletion":86,"completion":391,"start":392,"enrollment":253,"conditions":393,"interventions":395},[94],"2028-05-01","2023-11-01",[394],"Diabetes Mellitus Type 2",[87],{"nctId":397,"briefTitle":398,"status":399,"phases":400,"primaryCompletion":401,"completion":402,"start":403,"enrollment":247,"conditions":404,"interventions":406},"NCT02808182","Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)","COMPLETED",[94],"2020-12","2021-05","2017-01-17",[405],"Impaired Glucose Tolerance",[407],"Nicotinic acid",{"intervention":63,"totalTrials":98,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":420},{"trials":411,"activeCount":102},[],{"trials":413,"activeCount":102},[],{"trials":415,"activeCount":102},[],{"trials":417,"activeCount":102},[],{"trials":419,"activeCount":102},[],{"trials":421,"activeCount":98,"soonestReadout":62},[422],{"nctId":60,"briefTitle":61,"status":112,"phases":423,"primaryCompletion":62,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":429},[94],"2027-03-30","2019-12-09",16,[428],"Lipoprotein Lipase Deficiency",[63],{"intervention":58,"totalTrials":98,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":433,"activeCount":102},[],{"trials":435,"activeCount":102},[],{"trials":437,"activeCount":102},[],{"trials":439,"activeCount":102},[],{"trials":441,"activeCount":102},[],{"trials":443,"activeCount":98,"soonestReadout":57},[444],{"nctId":55,"briefTitle":56,"status":112,"phases":445,"primaryCompletion":57,"completion":57,"start":446,"enrollment":253,"conditions":447,"interventions":449},[94],"2025-11-01",[448],"Cardiovascular",[58],{"intervention":451,"totalTrials":98,"cells":452},"Niacin",{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":461,"NA":463},{"trials":454,"activeCount":102},[],{"trials":456,"activeCount":102},[],{"trials":458,"activeCount":102},[],{"trials":460,"activeCount":102},[],{"trials":462,"activeCount":102},[],{"trials":464,"activeCount":98,"soonestReadout":469},[465],{"nctId":466,"briefTitle":467,"status":112,"phases":468,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":477},"NCT06843148","Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.",[94],"2030-03","2030-07","2026-04",36,[474,475,476],"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Liver Fibrosis\u002FNASH","Non-Alcoholic Steato-Hepatitis (NASH)",[451],{"intervention":53,"totalTrials":98,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":490},{"trials":481,"activeCount":102},[],{"trials":483,"activeCount":102},[],{"trials":485,"activeCount":102},[],{"trials":487,"activeCount":102},[],{"trials":489,"activeCount":102},[],{"trials":491,"activeCount":98,"soonestReadout":52},[492],{"nctId":50,"briefTitle":51,"status":244,"phases":493,"primaryCompletion":52,"completion":494,"start":495,"enrollment":496,"conditions":497,"interventions":501},[],"2027-06-01","2024-11-01",18,[498,499,500],"First Episose Psychosis","Metabolic Disease","Psychosis; Episode",[53],{"intervention":503,"totalTrials":98,"cells":504},"Levothyroxine supplementation",{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":511,"PHASE4":513,"NA":527},{"trials":506,"activeCount":102},[],{"trials":508,"activeCount":102},[],{"trials":510,"activeCount":102},[],{"trials":512,"activeCount":102},[],{"trials":514,"activeCount":102},[515],{"nctId":516,"briefTitle":517,"status":518,"phases":519,"primaryCompletion":520,"completion":521,"start":522,"enrollment":253,"conditions":523,"interventions":526},"NCT02316743","Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism","UNKNOWN",[93],"2015-06","2015-07","2014-12",[524,525],"Systolic Heart Failure","Sub-clinical Hypothyroidism",[503],{"trials":528,"activeCount":102},[],{"intervention":530,"totalTrials":98,"cells":531},"quetiapine",{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":536,"PHASE3":538,"PHASE4":540,"NA":552},{"trials":533,"activeCount":102},[],{"trials":535,"activeCount":102},[],{"trials":537,"activeCount":102},[],{"trials":539,"activeCount":102},[],{"trials":541,"activeCount":102},[542],{"nctId":543,"briefTitle":544,"status":399,"phases":545,"primaryCompletion":546,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":551},"NCT00983320","Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study",[93],"2011-10","2008-04",52,[550],"Fibromyalgia",[530],{"trials":553,"activeCount":102},[],{"intervention":555,"totalTrials":98,"cells":556},"Topamax",{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":563,"PHASE4":565,"NA":583},{"trials":558,"activeCount":102},[],{"trials":560,"activeCount":102},[],{"trials":562,"activeCount":102},[],{"trials":564,"activeCount":102},[],{"trials":566,"activeCount":102},[567],{"nctId":568,"briefTitle":569,"status":518,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":581},"NCT04759196","Generating Evidence on NonEpileptic, Stereotypical and Intermittent Symptoms (NESIS) in Chronic Subdural Hematomas",[93],"2024-09","2024-12","2021-03-01",56,[576,577,578,579,580],"Chronic Subdural Hematoma","Epilepsy; Seizure","Cortical Depression; Cortical Depolarization","Nonepileptic, Stereotypical and Intermittent Symptoms","NESIS",[555,582],"Levetiracetam",{"trials":584,"activeCount":102},[],{"intervention":582,"totalTrials":98,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":595,"NA":601},{"trials":588,"activeCount":102},[],{"trials":590,"activeCount":102},[],{"trials":592,"activeCount":102},[],{"trials":594,"activeCount":102},[],{"trials":596,"activeCount":102},[597],{"nctId":568,"briefTitle":569,"status":518,"phases":598,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":599,"interventions":600},[93],[576,577,578,579,580],[555,582],{"trials":602,"activeCount":102},[],{"intervention":604,"totalTrials":98,"cells":605},"Brand name travoprost",{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":614,"NA":628},{"trials":607,"activeCount":102},[],{"trials":609,"activeCount":102},[],{"trials":611,"activeCount":102},[],{"trials":613,"activeCount":102},[],{"trials":615,"activeCount":102},[616],{"nctId":617,"briefTitle":618,"status":399,"phases":619,"primaryCompletion":620,"completion":620,"start":621,"enrollment":622,"conditions":623,"interventions":626},"NCT02796560","Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension",[93],"2017-09-12","2016-07-01",76,[624,625],"Glaucoma, Primary Open Angle","Ocular Hypertension",[604,627],"Generic travoprost",{"trials":629,"activeCount":102},[],{"intervention":627,"totalTrials":98,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":640,"NA":646},{"trials":633,"activeCount":102},[],{"trials":635,"activeCount":102},[],{"trials":637,"activeCount":102},[],{"trials":639,"activeCount":102},[],{"trials":641,"activeCount":102},[642],{"nctId":617,"briefTitle":618,"status":399,"phases":643,"primaryCompletion":620,"completion":620,"start":621,"enrollment":622,"conditions":644,"interventions":645},[93],[624,625],[604,627],{"trials":647,"activeCount":102},[],{"intervention":649,"totalTrials":98,"cells":650},"20% ASED + AT",{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":659,"NA":674},{"trials":652,"activeCount":102},[],{"trials":654,"activeCount":102},[],{"trials":656,"activeCount":102},[],{"trials":658,"activeCount":102},[],{"trials":660,"activeCount":102},[661],{"nctId":662,"briefTitle":663,"status":518,"phases":664,"primaryCompletion":42,"completion":471,"start":665,"enrollment":666,"conditions":667,"interventions":672},"NCT06294015","Efficacy of 20% Autologous Serum Drops in the Treatment of Corneal Epitheliopathy Associated With Antihypertensive Glaucoma Drops.",[93],"2024-03",25,[668,669,670,671],"Corneal Epitheliopathy","Glaucoma","Corneal Disease","Dry Eye",[649,673],"0.9% NS + AT",{"trials":675,"activeCount":102},[],{"intervention":673,"totalTrials":98,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":686,"NA":692},{"trials":679,"activeCount":102},[],{"trials":681,"activeCount":102},[],{"trials":683,"activeCount":102},[],{"trials":685,"activeCount":102},[],{"trials":687,"activeCount":102},[688],{"nctId":662,"briefTitle":663,"status":518,"phases":689,"primaryCompletion":42,"completion":471,"start":665,"enrollment":666,"conditions":690,"interventions":691},[93],[668,669,670,671],[649,673],{"trials":693,"activeCount":102},[],{"intervention":695,"totalTrials":98,"cells":696},"Pregabalin",{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":703,"PHASE4":705,"NA":717},{"trials":698,"activeCount":102},[],{"trials":700,"activeCount":102},[],{"trials":702,"activeCount":102},[],{"trials":704,"activeCount":102},[],{"trials":706,"activeCount":102},[707],{"nctId":708,"briefTitle":709,"status":399,"phases":710,"primaryCompletion":711,"completion":711,"start":712,"enrollment":247,"conditions":713,"interventions":716},"NCT01158859","Effect of Preoperative Pregabalin on Propofol Induction Dose",[93],"2011-08","2010-04",[714,715],"Anesthesia, General","Laparoscopic Surgery",[695],{"trials":718,"activeCount":102},[],{"intervention":720,"totalTrials":98,"cells":721},"20% mannitol bolus administration",{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":730,"NA":744},{"trials":723,"activeCount":102},[],{"trials":725,"activeCount":102},[],{"trials":727,"activeCount":102},[],{"trials":729,"activeCount":102},[],{"trials":731,"activeCount":102},[732],{"nctId":733,"briefTitle":734,"status":518,"phases":735,"primaryCompletion":736,"completion":736,"start":737,"enrollment":738,"conditions":739,"interventions":742},"NCT01745081","Comparison of 20% Mannitol and 3% Hypertonic Saline for Cerebral Relaxation During Elective Supratentorial Craniotomies",[93],"2014-09","2012-09",80,[740,741],"Osmotherapy","Intracranial Pressure",[720,743],"Hypertonic saline 3% bolus administration",{"trials":745,"activeCount":102},[],{"intervention":743,"totalTrials":98,"cells":747},{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":762},{"trials":749,"activeCount":102},[],{"trials":751,"activeCount":102},[],{"trials":753,"activeCount":102},[],{"trials":755,"activeCount":102},[],{"trials":757,"activeCount":102},[758],{"nctId":733,"briefTitle":734,"status":518,"phases":759,"primaryCompletion":736,"completion":736,"start":737,"enrollment":738,"conditions":760,"interventions":761},[93],[740,741],[720,743],{"trials":763,"activeCount":102},[],{"intervention":765,"totalTrials":98,"cells":766},"Intrathecal Morphine\u002FSufentanil",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":773,"PHASE4":775,"NA":792},{"trials":768,"activeCount":102},[],{"trials":770,"activeCount":102},[],{"trials":772,"activeCount":102},[],{"trials":774,"activeCount":102},[],{"trials":776,"activeCount":102},[777],{"nctId":778,"briefTitle":779,"status":780,"phases":781,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":791},"NCT02152514","RCT Comparing Analgesia Post-VATS With Epimorph VS Placebo","TERMINATED",[93],"2015-05","2013-04",34,[786,787,788,789,790],"Thoracic Surgery, Video-assisted","Postoperative Pain","Rachianesthesia","Sufentanil","Morphine",[765],{"trials":793,"activeCount":102},[],{"intervention":795,"totalTrials":235,"cells":796},"Vitamin C",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":832,"NA":834},{"trials":798,"activeCount":102},[],{"trials":800,"activeCount":102},[],{"trials":802,"activeCount":102},[],{"trials":804,"activeCount":102},[805,818],{"nctId":806,"briefTitle":807,"status":399,"phases":808,"primaryCompletion":809,"completion":810,"start":811,"enrollment":812,"conditions":813,"interventions":816},"NCT04401150","Lessening Organ Dysfunction With VITamin C - COVID-19",[92],"2022-07-15","2022-12-06","2020-08-14",392,[795,814,815],"COVID-19","Hospitalized Patients",[795,817],"Control",{"nctId":819,"briefTitle":820,"status":399,"phases":821,"primaryCompletion":822,"completion":823,"start":824,"enrollment":825,"conditions":826,"interventions":831},"NCT03680274","Lessening Organ Dysfunction With VITamin C",[92],"2021-08-15","2022-01-24","2018-11-08",872,[827,795,828,814,829,830],"Sepsis","Intensive Care Unit","Pandemic","Coronavirus",[795],{"trials":833,"activeCount":102},[],{"trials":835,"activeCount":102},[],{"intervention":817,"totalTrials":98,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":850,"NA":852},{"trials":839,"activeCount":102},[],{"trials":841,"activeCount":102},[],{"trials":843,"activeCount":102},[],{"trials":845,"activeCount":102},[846],{"nctId":806,"briefTitle":807,"status":399,"phases":847,"primaryCompletion":809,"completion":810,"start":811,"enrollment":812,"conditions":848,"interventions":849},[92],[795,814,815],[795,817],{"trials":851,"activeCount":102},[],{"trials":853,"activeCount":102},[],{"intervention":855,"totalTrials":98,"cells":856},"Insulin",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":876,"NA":878},{"trials":858,"activeCount":102},[],{"trials":860,"activeCount":102},[],{"trials":862,"activeCount":102},[],{"trials":864,"activeCount":102},[865],{"nctId":866,"briefTitle":867,"status":399,"phases":868,"primaryCompletion":869,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":874},"NCT01215331","Gestational Diabetes: Insulin or Oral Hypoglycemic Agents?",[92],"2014-04","2016-05","2010-08",73,[30],[855,875],"Metformin, glyburide and insulin",{"trials":877,"activeCount":102},[],{"trials":879,"activeCount":102},[],{"intervention":875,"totalTrials":98,"cells":881},{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":894,"NA":896},{"trials":883,"activeCount":102},[],{"trials":885,"activeCount":102},[],{"trials":887,"activeCount":102},[],{"trials":889,"activeCount":102},[890],{"nctId":866,"briefTitle":867,"status":399,"phases":891,"primaryCompletion":869,"completion":870,"start":871,"enrollment":872,"conditions":892,"interventions":893},[92],[30],[855,875],{"trials":895,"activeCount":102},[],{"trials":897,"activeCount":102},[],{"intervention":899,"totalTrials":98,"cells":900},"CycloSPORINE Ophthalmic",{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":907,"PHASE4":919,"NA":921},{"trials":902,"activeCount":102},[],{"trials":904,"activeCount":102},[],{"trials":906,"activeCount":102},[],{"trials":908,"activeCount":102},[909],{"nctId":910,"briefTitle":911,"status":518,"phases":912,"primaryCompletion":913,"completion":913,"start":914,"enrollment":915,"conditions":916,"interventions":918},"NCT06392438","Cyclosporine and Intense Pulsed Light for Dry Eye in Contact Lens Users",[92],"2025-09","2024-04-25",44,[671,917],"Contact Lens Complication",[899],{"trials":920,"activeCount":102},[],{"trials":922,"activeCount":102},[],{"intervention":924,"totalTrials":98,"cells":925},"vasopressin",{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":943,"NA":945},{"trials":927,"activeCount":102},[],{"trials":929,"activeCount":102},[],{"trials":931,"activeCount":102},[],{"trials":933,"activeCount":102},[934],{"nctId":935,"briefTitle":936,"status":399,"phases":937,"start":938,"enrollment":939,"conditions":940,"interventions":942},"NCT00269685","Comparison of Vasopressin and Other Pressors in Septic Shock",[91,92],"2000-07",20,[941],"Shock, Septic",[924],{"trials":944,"activeCount":102},[],{"trials":946,"activeCount":102},[],{"intervention":948,"totalTrials":98,"cells":949},"tinidazole+fluconazole vs metronidazole+clotrimazole",{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":956,"PHASE4":970,"NA":972},{"trials":951,"activeCount":102},[],{"trials":953,"activeCount":102},[],{"trials":955,"activeCount":102},[],{"trials":957,"activeCount":102},[958],{"nctId":959,"briefTitle":960,"status":399,"phases":961,"completion":962,"start":963,"enrollment":964,"conditions":965,"interventions":969},"NCT00313131","Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments",[92],"2005-05","2004-01",1524,[966,967,968],"Bacterial Vaginosis","Candidiasis","Vaginitis",[948],{"trials":971,"activeCount":102},[],{"trials":973,"activeCount":102},[],{"intervention":975,"totalTrials":98,"cells":976},"Budesonide 0.5 MG\u002FML",{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":996,"NA":998},{"trials":978,"activeCount":102},[],{"trials":980,"activeCount":102},[],{"trials":982,"activeCount":102},[],{"trials":984,"activeCount":102},[985],{"nctId":986,"briefTitle":987,"status":780,"phases":988,"primaryCompletion":989,"completion":990,"start":991,"enrollment":472,"conditions":992,"interventions":994},"NCT03323866","Mometasone vs Budesonide in CRS With Polyposis",[92],"2022-05-01","2022-08-01","2017-05-01",[993],"Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis",[975,995],"Mometasone nasal spray",{"trials":997,"activeCount":102},[],{"trials":999,"activeCount":102},[],{"intervention":995,"totalTrials":98,"cells":1001},{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1008,"PHASE4":1014,"NA":1016},{"trials":1003,"activeCount":102},[],{"trials":1005,"activeCount":102},[],{"trials":1007,"activeCount":102},[],{"trials":1009,"activeCount":102},[1010],{"nctId":986,"briefTitle":987,"status":780,"phases":1011,"primaryCompletion":989,"completion":990,"start":991,"enrollment":472,"conditions":1012,"interventions":1013},[92],[993],[975,995],{"trials":1015,"activeCount":102},[],{"trials":1017,"activeCount":102},[],{"intervention":1019,"totalTrials":98,"cells":1020},"Lovastatin",{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1022,"activeCount":102},[],{"trials":1024,"activeCount":102},[],{"trials":1026,"activeCount":102},[1027],{"nctId":1028,"briefTitle":1029,"status":399,"phases":1030,"primaryCompletion":520,"completion":520,"start":1031,"enrollment":9,"conditions":1032,"interventions":1034},"NCT02389868","Effects of Lovastatin on Human Platelet Proteome",[91],"2015-02",[1033],"Blood Platelets Proteome",[1019],{"trials":1036,"activeCount":102},[],{"trials":1038,"activeCount":102},[],{"trials":1040,"activeCount":102},[],{"intervention":1042,"totalTrials":98,"cells":1043},"Prolastin",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1045,"activeCount":102},[],{"trials":1047,"activeCount":102},[],{"trials":1049,"activeCount":102},[1050],{"nctId":1051,"briefTitle":1052,"status":780,"phases":1053,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":11,"conditions":1057,"interventions":1059},"NCT02010411","Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis",[91],"2004-10","2005-10","2004-06",[1058],"Cystic Fibrosis",[1042],{"trials":1061,"activeCount":102},[],{"trials":1063,"activeCount":102},[],{"trials":1065,"activeCount":102},[],{"intervention":1067,"totalTrials":98,"cells":1068},"POST Triheptanoin",{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1070,"activeCount":102},[],{"trials":1072,"activeCount":102},[],{"trials":1074,"activeCount":102},[1075],{"nctId":1076,"briefTitle":1077,"status":399,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":9,"conditions":1081,"interventions":1083},"NCT02679235","Brain Energy and Aging With Triheptanoin",[90,91],"2018-08-08","2016-04",[1082],"Frontal Lobe Hypometabolism",[1067],{"trials":1085,"activeCount":102},[],{"trials":1087,"activeCount":102},[],{"trials":1089,"activeCount":102},[],{"intervention":1091,"totalTrials":98,"cells":1092},"Montelukast",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1110,"PHASE4":1112,"NA":1114},{"trials":1094,"activeCount":102},[],{"trials":1096,"activeCount":102},[],{"trials":1098,"activeCount":102},[1099],{"nctId":1100,"briefTitle":1101,"status":518,"phases":1102,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1109},"NCT02108886","Pilot Study Testing a New Strategy for Management of Spontaneous Preterm Birth",[91],"2014-07","2015-12","2011-12",100,[1108],"Preterm Labor",[1091],{"trials":1111,"activeCount":102},[],{"trials":1113,"activeCount":102},[],{"trials":1115,"activeCount":102},[],{"intervention":1117,"totalTrials":98,"cells":1118},"Metformin",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1134,"PHASE4":1136,"NA":1138},{"trials":1120,"activeCount":102},[],{"trials":1122,"activeCount":102},[],{"trials":1124,"activeCount":102},[1125],{"nctId":1126,"briefTitle":1127,"status":399,"phases":1128,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":9,"conditions":1132,"interventions":1133},"NCT03722290","Metformin in Children and Adults With Fragile X Syndrome",[91],"2019-10-24","2020-11-01","2018-09-01",[249],[1117],{"trials":1135,"activeCount":102},[],{"trials":1137,"activeCount":102},[],{"trials":1139,"activeCount":102},[],{"intervention":1141,"totalTrials":98,"cells":1142},"Minocycline, then Minocycline\u002FLovastatin",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1160,"PHASE4":1162,"NA":1164},{"trials":1144,"activeCount":102},[],{"trials":1146,"activeCount":102},[],{"trials":1148,"activeCount":102},[1149],{"nctId":1150,"briefTitle":1151,"status":399,"phases":1152,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":1157,"interventions":1158},"NCT02680379","Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome",[91],"2017-10","2017-11","2016-03",22,[249],[1141,1159],"Lovastatin, then Minocycline\u002FLovastatin",{"trials":1161,"activeCount":102},[],{"trials":1163,"activeCount":102},[],{"trials":1165,"activeCount":102},[],{"intervention":1159,"totalTrials":98,"cells":1167},{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1178,"PHASE4":1180,"NA":1182},{"trials":1169,"activeCount":102},[],{"trials":1171,"activeCount":102},[],{"trials":1173,"activeCount":102},[1174],{"nctId":1150,"briefTitle":1151,"status":399,"phases":1175,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":1176,"interventions":1177},[91],[249],[1141,1159],{"trials":1179,"activeCount":102},[],{"trials":1181,"activeCount":102},[],{"trials":1183,"activeCount":102},[],{"intervention":1185,"totalTrials":98,"cells":1186},"Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).",{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1188,"activeCount":102},[],{"trials":1190,"activeCount":102},[],{"trials":1192,"activeCount":102},[1193],{"nctId":1194,"briefTitle":1195,"status":399,"phases":1196,"primaryCompletion":1197,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1202},"NCT00904618","Safety and Efficacy Study on the Implantation of the Tension-Free Vaginal Tape (TVT-Secur) Under Local Anesthesia",[91],"2009-03","2007-01",48,[1201],"Urinary Stress Incontinence",[1185],{"trials":1204,"activeCount":102},[],{"trials":1206,"activeCount":102},[],{"trials":1208,"activeCount":102},[],{"intervention":1210,"totalTrials":98,"cells":1211},"Propranolol Hydrochloride",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1228,"PHASE4":1230,"NA":1232},{"trials":1213,"activeCount":102},[],{"trials":1215,"activeCount":102},[],{"trials":1217,"activeCount":102},[1218],{"nctId":1219,"briefTitle":1220,"status":399,"phases":1221,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":1199,"conditions":1225,"interventions":1227},"NCT05085782","Reconsolidation Therapy With Propranolol as a Treatment for Chronic Pain",[91],"2024-12-30","2025-08-31","2022-02-07",[1226,550],"Chronic Low-back Pain",[1210],{"trials":1229,"activeCount":102},[],{"trials":1231,"activeCount":102},[],{"trials":1233,"activeCount":102},[],{"intervention":1235,"totalTrials":98,"cells":1236},"89Zr-DFO-AP-101",{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1251,"PHASE3":1253,"PHASE4":1255,"NA":1257},{"trials":1238,"activeCount":102},[],{"trials":1240,"activeCount":102},[1241],{"nctId":1242,"briefTitle":1243,"status":399,"phases":1244,"primaryCompletion":1222,"completion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1250},"NCT05974579","Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis",[90],"2026-03-31","2023-11-23",8,[1249],"Amyotrophic Lateral Sclerosis",[1235],{"trials":1252,"activeCount":102},[],{"trials":1254,"activeCount":102},[],{"trials":1256,"activeCount":102},[],{"trials":1258,"activeCount":102},[],{"intervention":1260,"totalTrials":235,"cells":1261},"Adalimumab",{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1268,"PHASE4":1270,"NA":1282},{"trials":1263,"activeCount":102},[],{"trials":1265,"activeCount":102},[],{"trials":1267,"activeCount":102},[],{"trials":1269,"activeCount":102},[],{"trials":1271,"activeCount":102},[1272],{"nctId":1273,"briefTitle":1274,"status":518,"phases":1275,"primaryCompletion":1276,"completion":1277,"start":1278,"enrollment":347,"conditions":1279,"interventions":1281},"NCT02035800","Bone Resorption, Osteoclastogenesis and Adalimumab",[93],"2018-12","2019-12","2013-05",[1280],"RheumatoId Arthritis",[1260],{"trials":1283,"activeCount":102},[1284],{"nctId":1285,"briefTitle":1274,"status":399,"phases":1286,"primaryCompletion":1287,"completion":1288,"start":1289,"enrollment":1290,"conditions":1291,"interventions":1293},"NCT00814866",[94],"2010-09","2011-03","2008-09",28,[1292],"Rheumatoid Arthritis",[1260],{"intervention":1295,"totalTrials":98,"cells":1296},"Mirbetriq",{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1298,"activeCount":102},[],{"trials":1300,"activeCount":102},[],{"trials":1302,"activeCount":102},[],{"trials":1304,"activeCount":102},[],{"trials":1306,"activeCount":102},[],{"trials":1308,"activeCount":102},[1309],{"nctId":1310,"briefTitle":1311,"status":399,"phases":1312,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":1156,"conditions":1316,"interventions":1317},"NCT02811289","Pharmacological Activation of Brown Adipose Tissue Metabolism",[94],"2018-05-24","2018-07-05","2016-08-05",[24],[1295],{"intervention":1319,"totalTrials":98,"cells":1320},"fentanyl",{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1325,"PHASE3":1327,"PHASE4":1329,"NA":1331},{"trials":1322,"activeCount":102},[],{"trials":1324,"activeCount":102},[],{"trials":1326,"activeCount":102},[],{"trials":1328,"activeCount":102},[],{"trials":1330,"activeCount":102},[],{"trials":1332,"activeCount":102},[1333],{"nctId":1334,"briefTitle":1335,"status":399,"phases":1336,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1345},"NCT01544959","Postoperative Analgesia Impact of Narcotic Free Anesthesia",[94],"2013-01","2018-05","2010-01",84,[1342,1343,1344],"Pain, Postoperative","Breast Cancer","Postoperative Nausea and Vomiting",[1319,1346],"beta-blocker",{"intervention":1346,"totalTrials":98,"cells":1348},{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1355,"PHASE4":1357,"NA":1359},{"trials":1350,"activeCount":102},[],{"trials":1352,"activeCount":102},[],{"trials":1354,"activeCount":102},[],{"trials":1356,"activeCount":102},[],{"trials":1358,"activeCount":102},[],{"trials":1360,"activeCount":102},[1361],{"nctId":1334,"briefTitle":1335,"status":399,"phases":1362,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":1340,"conditions":1363,"interventions":1364},[94],[1342,1343,1344],[1319,1346],{"intervention":1366,"totalTrials":98,"cells":1367},"Prometrium",{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1369,"activeCount":102},[],{"trials":1371,"activeCount":102},[],{"trials":1373,"activeCount":102},[],{"trials":1375,"activeCount":102},[],{"trials":1377,"activeCount":102},[],{"trials":1379,"activeCount":102},[1380],{"nctId":1381,"briefTitle":1382,"status":399,"phases":1383,"primaryCompletion":1384,"completion":1384,"start":1385,"enrollment":1386,"conditions":1387,"interventions":1390},"NCT03227705","Canadian Study on the Association of Pessary With Progesterone",[94],"2022-10-06","2018-06-04",79,[1388,1389],"Preterm Birth","Short Cervix",[1366],{"intervention":1392,"totalTrials":98,"cells":1393},"Self-adjustment of medication",{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1400,"PHASE4":1402,"NA":1404},{"trials":1395,"activeCount":102},[],{"trials":1397,"activeCount":102},[],{"trials":1399,"activeCount":102},[],{"trials":1401,"activeCount":102},[],{"trials":1403,"activeCount":102},[],{"trials":1405,"activeCount":102},[1406],{"nctId":1407,"briefTitle":1408,"status":518,"phases":1409,"primaryCompletion":1410,"completion":1411,"start":1412,"enrollment":247,"conditions":1413,"interventions":1415},"NCT05066971","Rate Control Self-adjustment in Patients With Permanent or Persistent Atrial Fibrillation Using Device Home Monitoring",[94],"2024-06-15","2025-06-15","2022-07-01",[1414],"Atrial Fibrillation, Persistent",[1392],{"intervention":1417,"totalTrials":98,"cells":1418},"allopurinol",{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1425,"PHASE4":1427,"NA":1429},{"trials":1420,"activeCount":102},[],{"trials":1422,"activeCount":102},[],{"trials":1424,"activeCount":102},[],{"trials":1426,"activeCount":102},[],{"trials":1428,"activeCount":102},[],{"trials":1430,"activeCount":102},[1431],{"nctId":1432,"briefTitle":1433,"status":1434,"phases":1435,"primaryCompletion":1436,"completion":1437,"enrollment":102,"conditions":1438,"interventions":1440},"NCT01775098","Allopurinol in Acute Gout","WITHDRAWN",[94],"2012-12","2013-02",[1439],"Gout",[1417],{"intervention":1442,"totalTrials":98,"cells":1443},"Oral Nicotinic acid",{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1450,"PHASE4":1452,"NA":1454},{"trials":1445,"activeCount":102},[],{"trials":1447,"activeCount":102},[],{"trials":1449,"activeCount":102},[],{"trials":1451,"activeCount":102},[],{"trials":1453,"activeCount":102},[],{"trials":1455,"activeCount":102},[1456],{"nctId":1457,"briefTitle":1458,"status":399,"phases":1459,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":31,"conditions":1463,"interventions":1464},"NCT05092945","Brown Adipose Tissue Metabolism in Type 2 Diabetes",[94],"2022-02-10","2025-08-18","2021-05-18",[24],[1442],{"intervention":1466,"totalTrials":98,"cells":1467},"methylprednisolone",{"EARLY_PHASE1":1468,"PHASE1":1470,"PHASE2":1472,"PHASE3":1474,"PHASE4":1476,"NA":1478},{"trials":1469,"activeCount":102},[],{"trials":1471,"activeCount":102},[],{"trials":1473,"activeCount":102},[],{"trials":1475,"activeCount":102},[],{"trials":1477,"activeCount":102},[],{"trials":1479,"activeCount":102},[1480],{"nctId":1481,"briefTitle":1482,"status":518,"phases":1483,"primaryCompletion":1484,"completion":1104,"start":1485,"enrollment":247,"conditions":1486,"interventions":1488},"NCT02036125","Carpal Tunnel Syndrome - Randomized Clinical Trial Evaluating Effectiveness of Ultrasound in Corticosteroid Injection",[94],"2015-10","2013-10",[1487],"Carpal Tunnel Syndrome",[1466],{"intervention":1490,"totalTrials":98,"cells":1491},"lidocaine",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1493,"activeCount":102},[],{"trials":1495,"activeCount":102},[],{"trials":1497,"activeCount":102},[],{"trials":1499,"activeCount":102},[],{"trials":1501,"activeCount":102},[],{"trials":1503,"activeCount":102},[1504],{"nctId":1505,"briefTitle":1506,"status":399,"phases":1507,"primaryCompletion":1508,"completion":1508,"start":546,"enrollment":1509,"conditions":1510,"interventions":1512},"NCT01455350","Efficacy of a Physiotherapy Treatment in Women Suffering From Provoked Vestibulodynia",[94],"2015-11",212,[1511],"Vestibulodynia",[1490],{"intervention":1514,"totalTrials":98,"cells":1515},"Formoterol Fumarate 12 micrograms Inhalation Powder",{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1517,"activeCount":102},[],{"trials":1519,"activeCount":102},[],{"trials":1521,"activeCount":102},[],{"trials":1523,"activeCount":102},[],{"trials":1525,"activeCount":102},[],{"trials":1527,"activeCount":102},[1528],{"nctId":1529,"briefTitle":1530,"status":399,"phases":1531,"primaryCompletion":1532,"completion":1532,"start":1533,"enrollment":22,"conditions":1534,"interventions":1535},"NCT05553184","Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10)",[94],"2023-05-29","2022-07-05",[24,21],[1514,1536],"Nicotinic Acid 50 MG Oral",{"intervention":1536,"totalTrials":98,"cells":1538},{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1545,"PHASE4":1547,"NA":1549},{"trials":1540,"activeCount":102},[],{"trials":1542,"activeCount":102},[],{"trials":1544,"activeCount":102},[],{"trials":1546,"activeCount":102},[],{"trials":1548,"activeCount":102},[],{"trials":1550,"activeCount":102},[1551],{"nctId":1529,"briefTitle":1530,"status":399,"phases":1552,"primaryCompletion":1532,"completion":1532,"start":1533,"enrollment":22,"conditions":1553,"interventions":1554},[94],[24,21],[1514,1536],{"intervention":1556,"totalTrials":98,"cells":1557},"Canagliflozin 100mg",{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1562,"PHASE3":1564,"PHASE4":1566,"NA":1568},{"trials":1559,"activeCount":102},[],{"trials":1561,"activeCount":102},[],{"trials":1563,"activeCount":102},[],{"trials":1565,"activeCount":102},[],{"trials":1567,"activeCount":102},[],{"trials":1569,"activeCount":102},[1570],{"nctId":1571,"briefTitle":1572,"status":1434,"phases":1573,"primaryCompletion":1574,"completion":1574,"start":1575,"enrollment":102,"conditions":1576,"interventions":1578},"NCT03298009","Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)",[94],"2018-06-30","2018-05-01",[1577,36],"Type2 Diabetes",[1556],{"intervention":1580,"totalTrials":98,"cells":1581},"Mirabegron",{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1588,"PHASE4":1590,"NA":1592},{"trials":1583,"activeCount":102},[],{"trials":1585,"activeCount":102},[],{"trials":1587,"activeCount":102},[],{"trials":1589,"activeCount":102},[],{"trials":1591,"activeCount":102},[],{"trials":1593,"activeCount":102},[1594],{"nctId":1595,"briefTitle":1596,"status":399,"phases":1597,"primaryCompletion":1598,"completion":1598,"start":1599,"enrollment":25,"conditions":1600,"interventions":1601},"NCT04823442","Activation of Brown Adipose Tissue Metabolism Using Mirabegron",[94],"2022-04-04","2021-01-21",[24],[1580,1602],"Bisoprolol Fumarate",{"intervention":1602,"totalTrials":98,"cells":1604},{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1609,"PHASE3":1611,"PHASE4":1613,"NA":1615},{"trials":1606,"activeCount":102},[],{"trials":1608,"activeCount":102},[],{"trials":1610,"activeCount":102},[],{"trials":1612,"activeCount":102},[],{"trials":1614,"activeCount":102},[],{"trials":1616,"activeCount":102},[1617],{"nctId":1595,"briefTitle":1596,"status":399,"phases":1618,"primaryCompletion":1598,"completion":1598,"start":1599,"enrollment":25,"conditions":1619,"interventions":1620},[94],[24],[1580,1602]]